US20060014983A1 - Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride - Google Patents

Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride Download PDF

Info

Publication number
US20060014983A1
US20060014983A1 US11/135,647 US13564705A US2006014983A1 US 20060014983 A1 US20060014983 A1 US 20060014983A1 US 13564705 A US13564705 A US 13564705A US 2006014983 A1 US2006014983 A1 US 2006014983A1
Authority
US
United States
Prior art keywords
compound
formula
trihydrochloride
added
hydroxymethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
US11/135,647
Other versions
US7189879B2 (en
Inventor
Johannes Platzek
Jan Huebner
Orlin Petrov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE200410026102 external-priority patent/DE102004026102B4/en
Application filed by Schering AG filed Critical Schering AG
Priority to US11/135,647 priority Critical patent/US7189879B2/en
Assigned to SCHERING AG reassignment SCHERING AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PETROV, ORLIN, HUEBNER, JAN, PLATZEK, JOHANNES
Publication of US20060014983A1 publication Critical patent/US20060014983A1/en
Application granted granted Critical
Publication of US7189879B2 publication Critical patent/US7189879B2/en
Assigned to BAYER SCHERING PHARMA AKTIENGESELLSCHAFT reassignment BAYER SCHERING PHARMA AKTIENGESELLSCHAFT CHANGE OF NAME (SEE DOCUMENT FOR DETAILS). Assignors: SCHERING AKTIENGESELLSCHAFT
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • C07C213/08—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton by reactions not involving the formation of amino groups, hydroxy groups or etherified or esterified hydroxy groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/10—Oxygen atoms
    • C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers

Abstract

A new process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride is described.

Description

  • This application claims the benefit of the filing date of U.S. Provisional Application Ser. No. 60/575,838 filed Jun. 2, 2004 which is incorporated by reference herein.
  • The invention relates to the subject that is characterized in the claims, i.e., a new process for the production of 1 -hydroxymethyl-1,3,5-triazapentane, trihydrochloride.
  • The use of contrast media for visualizing the intravascular space (blood-pool imaging) is one of the important applications in MRI angiography. In this connection, a compound, the so-called MS-325 (U.S. Pat. No. 6,676,929 and WO 96/23526), which already successfully completed phase III clinical testing and has been filed with the FDA for approval, has proven its value especially well. The synthesis of MS-325 is described in Synthetic Communications, 26(13), 2511-2522 (1996) and Synthetic Communications, 29(14), 2377-2391 (1999).
  • Within the scope of the development of this compound, it was desired to provide larger amounts of substance. Since the substance is administered to humans, strict standards on the purity of the final product as well as on the intermediate products must be set. Based on the large range of applications to be expected, such a high-grade product should also be producible at a representative cost (in terms of price). There is therefore a desire to have as economically advantageous a synthesis as possible. A very important intermediate product of the synthesis of MS-325 is the 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride. (I)
    Figure US20060014983A1-20060119-C00001
  • In addition to the synthesis that is described in U.S. Pat. No. 6,676,929 and WO 96/23526, 2 synthesis methods are described in detail:
    1st Method (Synthetic Communications, 26(13), 2511-2522 (1996))
    Figure US20060014983A1-20060119-C00002
  • The total yield of the synthesis is: 54.2% of theory.
  • The very costly starting material O-benzyl-Boc-serine, which is obtained by a very loss-prone alkylation of the Boc-serine and is difficult to clean, is disadvantageous in this synthesis (probably a research synthesis on a laboratory scale). The production of the primary alcohol from the acid is performed via a mixed anhydride formation by in-situ reduction with sodium borohydride. Specifically when scaling such reactions up to the 100 kg scale, problems can be expected, since extended addition times and exothermal reactions cause the anhydride to decompose. In addition, the use of larger amounts of trifluoroacetic acid, which is used in the cleavage of the BOC group, is not optimal not only for reasons of cost but also for aspects of environmental politics. In addition, the synthesis contains a chromatographic purification, which, out of concern for the operational process, is to be avoided as much as possible.
    2nd Method (Synthetic Communications, 29(14), 2377-2391 (1999)
    Figure US20060014983A1-20060119-C00003
  • The total yield of the synthesis is: 57.9% of theory.
  • A great drawback of this synthesis is the use of the very costly borane-THF complex (Aldrich 2003/2004: 20 liters of 1.0 M borane-tetrahydrofuran complex 2403.10 EURO !), which is used in 3× excess (!). In addition, a heavy dilution, which hinders up-scaling, of about 16×THF relative to the charging material is noteworthy. The handling of diborane on an industrial scale (1000-8000 l stirrer) is in any case problematical and of concern with respect to safety. Fatal incidents in handling large amounts of diborane solution have already been reported (Pfizer). In addition, the boric acid that accumulates with the working-up is to be filtered off, which is very difficult as far as processing is concerned.
  • To produce larger amounts of MS-325 (i.e., production of several thousand kilograms of product after introduction on the market), there is a great need to develop as economical a synthesis as possible for the 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride, (1).
  • This process satisfies the set requirements to a large extent.
  • The compound of formula I
    Figure US20060014983A1-20060119-C00004
    is produced by cleavage of the Z protective group or the Boc-protective group from compounds of formula IIa or IIb
    Figure US20060014983A1-20060119-C00005
  • The cleavage is carried out according to the methods of protective group cleavage for amines that are known to one skilled in the art and subsequent conversion into the hydrochlorides. The cleavage of the Z and Boc group is described in T. W. Green, Protective Groups in Organic Synthesis, John Wiley & Sons, N.Y., 1981 and in P. J. Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, 1994.
  • In the case of the BOC protective group, the cleavage of the BOC group is carried out by treatment with aqueous hydrochloric acid (5% up to concentrated HCl), at temperatures of 0 to 100° C., preferably 20-80° C. The trihydrochloride can be precipitated by adding an alcohol, such as, e.g., ethanol, methanol, isopropanol, n-butanol, isobutanol or mixtures of these alcohols, or mixtures of these alcohols with THF, methyl-tert-methyl ether or acetone and can be isolated in crystalline form. In many cases, it has proven advantageous to concentrate by evaporation the aqueous hydrochloric acid solution before the organic solvent is added.
  • In the case of the Z protective group, the cleavage of the Z group is carried out by treatment with aqueous hydrochloric acid (10% up to concentrated HCl), at temperatures of 0 to 100° C., preferably 60-100° C., or by catalytic hydrogenation on Pd/C in aqueous solution. Mixtures of water with ethanol, methanol or THF can also be used optionally with the addition of aqueous hydrochloric acid for hydrogenation. The hydrogenation is carried out at 10-60° C., preferably at room temperature, at pressures of 2-10 bar. After the catalyst is filtered off, the product-containing filtrate is worked up.
  • The trihydrochloride (I) can be precipitated by adding an alcohol, such as, e.g., ethanol, methanol, isopropanol, butanol, isobutanol or mixtures of these alcohols, preferably an ethanol/butanol mixture, or mixtures of these alcohols with THF, methyl-tert-butyl methyl ether or acetone and can be isolated in crystalline form. In many cases, it has proven advantageous to concentrate by evaporation the aqueous hydrochloric acid solution (even after hydrogenation) before adding the organic solvent.
  • The trihydrochloride (I) is dried in a vacuum (T=25-50° C./6-48 hours) and then obtained as a colorless, crystalline powder.
  • Of course, the hydrobromides, or, with sulfuric acid, the sulfates or hydrosulfates, etc., can also be produced by use of HBr instead of HCl.
  • Compounds of formulas IIa and IIb are obtained from compounds of general formulas IIIa and IIIb
    Figure US20060014983A1-20060119-C00006
    by cleavage of the THP protective group. The cleavage is carried out according to the methods of cleavage of THP-ether that are known to one skilled in the art; T. W. Green, Protective Groups in Organic Synthesis, John Wiley & Sons N.Y., 1981 and in P. J. Kocienski, Protecting Groups, Georg Thieme Verlag Stuttgart, 1994. Gupta, Priti; Fernandes, Rodney A.; Kumar, Pradeep; Tetrahedron Lett.; 44; 22; 2003; 4231-4232. Burton, T. S. et al.; J.Chem.Soc.Perkin Trans.1; 1976; 2550-2556; Evans, R. J. D. et al.; J.Chem.Soc.Perkin Trans. 1; 1974; 552-556.
  • The cleavage of the THP group is carried out in the way that the compounds of formulas IIIa and IIIb are dissolved in an alcohol, such as, e.g., ethanol, methanol, isopropanol, isobutanol or mixtures of these alcohols, or mixtures of these alcohols with water, THF, methyl-tert-butyl methyl ether or acetone, and a mineral acid, such as HCl, sulfuric acid, phosphoric acid, but preferably aqueous hydrochloric acid (10% up to concentrated HCl, preferably concentrated) is added and stirred at temperatures of 0-80° C., preferably 0 -50° C. The reaction time is 30 minutes to 12 hours, preferably 3 to 6. hours. The product precipitates during the reaction. To increase the yield, optionally THF, methyl-tert-butyl methyl ether or acetone can ultimately be added for complete crystallization.
  • The dihydrochlorides (IIa and IIb) are dried in a vacuum (T: 25-50° C.6 -48 hours) and then obtained as colorless, crystalline powder.
  • Compounds of formulas IIa and IIIb are obtained from compounds of formulas IVa and IVb
    Figure US20060014983A1-20060119-C00007
    in which X stands for a tosyloxy or a mesyloxy group
    by reaction with 1,2-diaminoethane.
  • The reaction is carried out at temperatures of 10 to 70° C., preferably 30-60° C. The reaction time is 3 to 12 hours, preferably 3-8 hours. The reaction can be performed either directly in pure diaminoethane, or by adding a solvent such as THF, dioxane, 2-methyl-THF, pyridine or alcohols, such as ethanol, methanol, isopropanol, or butanol. 10 to 40 molar equivalents, preferably 12 to 25 molar equivalents, of diaminoethane relative to IVa or IVb can be used.
  • For working-up, excess diaminoethane optionally can be distilled off in a vacuum, or, after adding water, the product can be extracted with suitable solvents, such as, e.g., THF, ethyl acetate, butanol, dichloromethane, or 2-methyl-THF.
  • The alkylation of diamines is described in, e.g.: Palmer, Brian D.; Lee, Ho H.; Johnson, Paul; Baguley, Bruce C.; Wickham, Geoffrey; et al.; J. Med. Chem.; 33; 11; 1990; 3008-3014.
  • Gibson, Dan; Gean, Keria-Fiorella; Ben-Shoshan, Raphael; Ramu, Avner; Ringel, Israel; Katzhendler, Jehoshua; J.Med.Chem.; 34; 1; 1991; 414-420.
  • Lee, Ho H.; Palmer, Brian D.; Baguley, Bruce C.; Chin, Michael; McFadyen, W. David; et al.; J.Med.Chem.; 35; 16; 1992; 2983-2987.
  • Skarzewski, Jacek; Daniluk, Ewa; Monatsh.Chem.; 114; 1983; 1071-1078. Sajiki, Hironao; Ong, Karen Y.; Nadler, Samuel T.; Wages, Heather E.; McMurry, Thomas J.; Synth.Commun.; 26; 13; 1996; 2511-2522.
  • EP 680467 (Schering AG).
  • In some cases, it has proven especially advantageous to produce the compound of formula I from compounds of formulas IIIa and IIIb by cleavage of THP and N protective group groups in a single-pot reaction.
  • In this connection, the cleavage of both protective groups is carried out by treatment with aqueous hydrochloric acid (5% to concentrated HCl) at temperatures of 0 to 100° C., preferably 20-95° C. The trihydrochloride can be precipitated by adding an alcohol, such as, e.g., ethanol, methanol, isopropanol, n-butanol, isobutanol or mixtures of these alcohols, or mixtures of these alcohols with THF, methyl-tert-butyl methyl ether or acetone and isolated in crystalline form. In many cases, it has proven advantageous to concentrate by evaporation the aqueous hydrochloric acid solution before the organic solvent is added.
  • Compounds of formulas IVa and IVb are obtained according to the methods, known to one skilled in the art, of mesylation or tosylation of the alcohols of general formulas Va and Vb
    Figure US20060014983A1-20060119-C00008
  • The reaction of alcohols Va or Vb is carried out with 1-1.5 equivalents of methane-sulfonic acid chloride or p-toluenesulfonic acid chloride in aprotic solvents, such as THF, 2-methyl-THF, dichloromethane, toluene, preferably THF with the addition of an amine, such as, e.g., triethylamine, Hünig base or pyridine, preferably triethylamine, at temperatures of −20° C. to +20° C., preferably −5 to +10° C. The reaction time is 1-12 hours, preferably 1-3 hours.
  • Literature:
  • Fukushi, Hideto; Mabuchi, Hiroshi; Terashita, Zen-ichi; Nishikawa, Kohei; Sugihara, Hirosada; Chem.Pharm.Bull.; 42; 3; 1994; 551-559.
  • Higashiura, Kunihiko; Morino, Hiroe; Matsuura, Hirohide; Toyomaki, Yoshio; Ienaga, Kazuharu; J.Chem.Soc.Perkin Trans.1; 1989; 1479-1481.
  • Donner, B. G.; Tetrahedron Lett.; 36; 8; 1995; 1223-1226.
  • Sajiki, Hironao; Ong, Karen Y.; Nadler, Samuel T.; Wages, Heather E.; McMurry, Thomas J.; Synth.Commun.; 26; 13; 1996; 2511-2522.
  • Journal; Sajiki, Hironao; Ong, Karen Y.; Nadler, Samuel T.; Wages, Heather E.; McMurry, Thomas J.; Synth.Commun.; 26; 13; 1996; 2511-2522.
  • Benoist, Eric; Loussouam, Anthony; Remaud, Patricia; Chatal, Jean-Francois; Gestin, Jean-Francois; Synthesis; 8; 1998; 1113-1118.
  • The compound IVb with X=p-toluenesulfoxy is known in the literature: Sasaki, N. Andre; Hashimoto, Chiyomi; Potier, Pierre; Tetrahedron Lett.; 28; 48; 1987; 6069-6072.
  • The compound Va is also known in the literature: Wang, Yi-Fong; Lalonde, James J.; Momongan, Milagros; Bergbreiter, David E.; Wong, Chi-Huey;
  • J.Amer.Chem.Soc.; 110; 21; 1988; 7200-7205.
  • The analogous BOC compound Vb is described in: Sasaki, N. Andre; Hashimoto, Chiyomi; Potier, Pierre; Tetrahedron Lett.; 28; 48; 1987; 6069-6072.
  • The use of mesylates IVa and IVb is preferred.
  • Compounds of general formula V are known in the literature.
  • The advantages of the new process are:
  • 1. Higher total yield compared to the prior art (see below)
  • 2. Simple procedure (no intermediate purification of the precursors)
  • 3. Reasonably-priced starting materials
  • 4. Crystalline intermediate compounds that make purification possible (important from the regulatory standpoint)
  • 5. Avoidance of DIBORANE (price/safety)
  • 6. Avoidance of trifluoroacetic acid
  • Based on the simplified procedure, it is made possible to easily and unproblematically produce batches on the multi-kg scale. The following two diagrams are used to illustrate the new process:
  • 1. Z Process (Two-Pot)
    Figure US20060014983A1-20060119-C00009
  • Total yield: 75% of theory
  • 2. Z Process (Single-Pot)
    Figure US20060014983A1-20060119-C00010
  • Total yield: 73% of theory
  • 3. Boc Process (Two-Pot)
    Figure US20060014983A1-20060119-C00011
  • Total yield: 71% of theory
  • 4. Boc Process (Single-Pot)
    Figure US20060014983A1-20060119-C00012
  • Total yield: 72% of theory
  • Although the one-pot processes are shorter, the two-pot processes are preferred for regulatory reasons, since they make possible an additional possibility of purification of intermediate compounds IIa or IIb.
  • The Z process is preferably used.
  • The total yields of the Z process and the Boc process are significantly higher in both cases than the process that is described in the literature. The simple implementation of these processes allows batches on the scale of up to 8000 l to be produced. In addition, the production costs, because of the higher total yield and the simpler performance of the process, have been significantly reduced.
  • The synthesis also allows the production of corresponding antipodes or else the racemate of target compound (I).
  • The examples below are used to explain the subject of the invention.
    • EXAMPLES Example 1 (Z Method/Two-Pot Process)
  • 1 a) 3-Aza-5-amino-1-(R)-hydroxymethyl-1-(benzyloxycarbonylamino)pentane, dihydrochloride
  • 500 g (1974.2 mmol) of (S)-Z-serine methyl ester is introduced into 2000 ml of tetrahydrofuran (THF) and 199.3 g (2369 mmol) of dihydropyran, and 100 mg of p-toluenesulfonic acid is added. It is heated for 6 hours at 60° C. After the reaction is completed, 1000 ml of solvent is distilled off (removal of excess dihydropyran).
  • 2000 ml of fresh THF is added, and 227 g (6.00 mol) of sodium borohydride is added, and it is cooled to 0° C. 2500 ml of methanol is slowly added in drops to this suspension, and the temperature is kept between 2° C. and 6° C. (gas generation). After the addition is completed, it is stirred for 3 more hours at 10° C. 4000 ml of water is added, and the organic solvent is distilled off to a large extent in a vacuum. Then, it is extracted two times with 2000 ml of ethyl acetate in each case. The combined ethyl acetate phases are largely concentrated by evaporation in a vacuum, and the remaining oil is taken up in 3000 ml of THF.
  • 405 g ( 4.00 mol) of triethylamine is added, and it is cooled to -5° C. Then, 248.7 g (2.17 mol) of methanesulfonic acid chloride is added in drops, and the temperature is kept between −5° C. to 0° C. After the addition is completed, it is stirred for one more hour at 0° C.
  • In the thus obtained solution, 1923 g (32 mol) of 1,2-diaminoethane is quickly added and stirred for 5 hours at 50° C. 6000 ml of water, as well as 176 g (4.4 mol) of sodium hydroxide and 200 g of sodium chloride are added and vigorously thoroughly stirred until all salts have dissolved. Then, 1000 ml of ethyl acetate is added and vigorously thoroughly stirred again. The organic phase is separated, and the aqueous phase is then re-extracted twice with a mixture that consists of 500 ml of THF/500 ml of ethyl acetate in each case. The combined organic phases are concentrated by evaporation in a vacuum, and the remaining oil is dissolved in 2500 ml of methanol. 180 ml of concentrated hydrochloric acid is added, and it is stirred for two hours at room temperature. Then, 3000 ml of methyl-tert-butyl ether is added, and it is cooled to 0° C. (in this case, the title compound completely crystallizes out). The crystals are filtered off and rewashed twice with a mixture that consists of cold methanol/methyl-tert-butyl ether 1:1. The crystals are dried for 8 hours at 40° C. in a vacuum.
  • Yield: 544.1 g of colorless crystals (81% of theory relative to the (S)-Z-serine methyl ester that is used)
  • Elementary analysis:
    Cld. C 45.89 H 6.81 N 12.35 Cl 20.84
    Fnd. C 46.12 H 7.02 N 12.22 Cl 20.71

    Cleavage of the Z Protective Group by Hydrogenation
    1b) 3-Aza-5-amino-1-(R)-hydroxymethyl-1-amino-pentane, trihydrochloride
  • 544.0 g (1599 mmol) of the title compound of Example la is dissolved in a mixture that consists of 4400 ml of methanol/1100 ml of water and 55 ml of concentrated hydrochloric acid, and it is hydrated over 8 g of hydrating catalyst Pd/C (10% Pd) at room temperature (6 bar). The catalyst is filtered off, and the filtrate is concentrated by evaporation in a vacuum as much as possible. The remaining oil is taken up with 950 ml of concentrated hydrochloric acid and stirred at room temperature (in this case, crystallization already sets in). Then, a mixture that consists of 2500 ml of ethanol/750 ml of n-butanol is carefully added in drops (in this case, the product crystallizes out). It is cooled to 0° C. and stirred for 3 hours at this temperature, the precipitated crystlals are filtered out, and it is rewashed twice with a mixture that consists of cold ethanol/n-butanol=3:1. Then, the crystals are dried in a vacuum at 50° C. (7 hours).
  • Yield: 360.7 g of colorless crystals (93% of theory)
  • Elementary analysis:
    Cld. C 24.76 H 7.48 N 17.32 Cl 43.85
    Fnd. C 24.59 H 7.61 N 17.14 Cl 43.62

    Total yield over all stages: 75% of theory
    • Example 2 (Z Method/One-Pot Process)
  • 3-Aza-5-amino-1-(R)-hydroxymethyl-1-amino-pentane, trihydrochloride
  • Analogously to what is described in Example 4, the Z intermediate compounds are converted in a single-pot variant into the target compound.
  • The cleavage of the Z protective group is carried out by acid hydrolysis with HCl.
  • To this end, intermediate compound IIIa is dissolved in concentrated hydrochloric acid and heated for 6 hours to 90° C. It is cooled to room temperature. Then, a mixture that consists of ethanol/n-butanol (3: 1) is carefully added in drops (in this case, the product crystallizes out). It is cooled to 0° C. and stirred for 3 hours at this temperature, the precipitated crystals are filtered off, and it is rewashed twice with a mixture that consists of cold ethanol/n-butanol=3:1. Then, the crystals are dried in a vacuum at 50° C. (7 hours).
  • Yield: Colorless crystals (91% of theory)
  • Elementary analysis:
    Cld. C 24.76 H 7.48 N 17.32 Cl 43.85
    Fnd. C 24.53 H 7.71 N 17.17 Cl 43.59

    Total yield over all stages: 73% of theory
    • Example 3 (Boc Method/Two-Pot Process)
  • 3-Aza-5-amino-1-(R)-hydroxymethyl-1-amino-pentane, trihydrochloride
  • Analogously to what is described in Example 1, the Boc intermediate compounds are converted in a two-pot process (with intermediate isolation of IIb) into the target compound.
  • Elementary analysis:
    Cld. C 24.76 H 7.48 N 17.32 Cl 43.85
    Fnd. C 24.50 H 7.67 N 17.13 Cl 43.64

    Total yield over all stages: 71% of theory
    • Example 4 (Boc Method/Single-Pot Process)
  • 3-Aza-5-amino-1-(R)-hydroxymethyl-1-amino-pentane, trihydrochloride
  • 433 g (1974.2 mmol) of (S)-Boc-serine methyl ester is introduced into 2000 ml of tetrahydrofuran (THF) and 199.3 g (2369 mmol) of dihydropyran, and 100 mg of p-toluenesulfonic acid is added. It is heated for 6 hours at 60° C. After the reaction is completed, 1000 ml of solvent is distilled off (removal of excess dihydropyran).
  • 2000 ml of fresh THF is added, and 227 g (6.00 mol) of sodium borohydride is added, and it is cooled to 0° C. 2500 ml of methanol is slowly added in drops to this suspension, and the temperature is kept between 2° C. and 6° C. (gas generation). After the addition is completed, it is stirred for 3 more hours at 10° C. 4000 ml of water is added, and the organic solvent is distilled off to a large extent in a vacuum. Then, it is extracted twice with 2000 ml of ethyl acetate in each case. The combined ethyl acetate phases are largely concentrated by evaporation in a vacuum, and the remaining oil is taken up in 3000 ml of THF.
  • 405 g (4.00 mol) of triethylamine is added and cooled to −5° C. Then, 248.7 g (2.17 mol) of methanesulfonic acid chloride is added in drops, and the temperature is kept between −5° C. to 0° C. After the addition is completed, it is stirred for one more hour at 0° C.
  • 1923 g (32 mol) of 1,2-diaminoethane is quickly added to the thus obtained solution, and it is stirred for 5 hours at 50° C. 6000 ml of water, as well as 176 g (4.4 mol) of sodium hydroxide and 200 g of sodium chloride are added and vigorously thoroughly stirred until all salts are dissolved. Then, 1000 ml of ethyl acetate is added, and it is vigorously thoroughly stirred again. The organic phase is separated, and the aqueous phase is then re-extracted twice with a mixture that consists of 500 ml of THF/500 ml of ethyl acetate in each case. The combined organic phases are concentrated by evaporation in a vacuum.
  • The remaining oil is dissolved in 1400 ml of concentrated hydrochloric acid, and it is heated for 6 hours to 90° C. It is cooled off to room temperature. Then, a mixture that consists of 3150 ml of ethanol/1050 ml of n-butanol is carefully added in drops (in this case, the product crystallizes out). It is cooled to 0° C. and stirred for 3 hours at this temperature, the precipitated crystals are filtered out, and it is rewashed twice with a mixture that consists of cold ethanol/n-butanol=3:1. Then, the crystals are dried in a vacuum at 50° C. (7 hours).
  • Total yield: 398 g of colorless crystals (72% of theory over all stages)
  • Elementary analysis:
    Cld. C 24.76 H 7.48 N 17.32 Cl 43.85
    Fnd. C 24.51 H 7.65 N 17.49 Cl 43.70
  • Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following preferred specific embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.
  • In the foregoing and in the following examples, all temperatures are set forth uncorrected in degrees Celsius and, all parts and percentages are by weight, unless otherwise indicated.
  • The entire disclosures of all applications, patents and publications, cited herein and of corresponding German application No. 10 2004 026 102.4, filed May 25, 2004 and U.S. Provisional Application Ser. No. 60/575,838, filed Jun. 2, 2004, are incorporated by reference herein.
  • The preceding examples can be repeated with similar success by substituting the generically or specifically described reactants and/or operating conditions of this invention for those used in the preceding examples.
  • From the foregoing description, one skilled in the art can easily ascertain the essential characteristics of this invention and, without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions.

Claims (9)

1. Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride (I),
Figure US20060014983A1-20060119-C00013
characterized in that
compounds of formula IVa or IVb
Figure US20060014983A1-20060119-C00014
in which X stands for an —OSO2Me or p-toluenesulfoxy group,
are reacted with 1,2-diaminoethane to form amines of formula IIIa or IIIb
Figure US20060014983A1-20060119-C00015
then the THP-protective group is cleaved off, and in the thus obtained compound IIa or IIb
Figure US20060014983A1-20060119-C00016
the protective groups that are located on the nitrogen atom are cleaved off.
2. Process for the production of l-hydroxymethyl-1,3,5-triazapentane, trihydrochloride (I),
Figure US20060014983A1-20060119-C00017
wherein
compounds of formulas IVa and IVb
Figure US20060014983A1-20060119-C00018
in which X stands for an —SO2Me or p-toluenesulfoxy group,
are reacted with 1,2-diaminoethane to form amines of formulas
Figure US20060014983A1-20060119-C00019
and subsequently all protective groups are cleaved off in a single-pot process.
3. Process for the production of the compound of formula I, according to claim 1
Figure US20060014983A1-20060119-C00020
wherein stages IIa, IIIa and IVa are passed through.
4. Compound of formula IIa
Figure US20060014983A1-20060119-C00021
5. Compound of formula IIb
Figure US20060014983A1-20060119-C00022
6. Compound of formula IIIa
Figure US20060014983A1-20060119-C00023
7. Compound of formula IIIb
Figure US20060014983A1-20060119-C00024
8. Process according to claim 1, wherein the corresponding enantiomers in IVa and IVb are used in the synthesis sequence.
9. Process according to claim 1, wherein the corresponding racemates of IVa and IVb are used in the synthesis sequence.
US11/135,647 2004-05-25 2005-05-24 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride Expired - Fee Related US7189879B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/135,647 US7189879B2 (en) 2004-05-25 2005-05-24 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DE102004026102.4 2004-05-25
DE200410026102 DE102004026102B4 (en) 2004-05-25 2004-05-25 Process for the preparation of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride
US57583804P 2004-06-02 2004-06-02
US11/135,647 US7189879B2 (en) 2004-05-25 2005-05-24 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride

Publications (2)

Publication Number Publication Date
US20060014983A1 true US20060014983A1 (en) 2006-01-19
US7189879B2 US7189879B2 (en) 2007-03-13

Family

ID=35600361

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/135,647 Expired - Fee Related US7189879B2 (en) 2004-05-25 2005-05-24 Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride

Country Status (1)

Country Link
US (1) US7189879B2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100010673A1 (en) * 2008-07-11 2010-01-14 Yulun Wang Tele-presence robot system with multi-cast features

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164289A1 (en) * 1995-02-01 2002-11-07 Mcmurry Thomas J. Diagnostic imaging contrast agents with extended blood retention

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3728525A1 (en) 1987-08-24 1989-03-16 Schering Ag MULTI-CORE SUBSTITUTED COMPLEX ILLUMINATORS, COMPLEX AND COMPLEX SALTS, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL AGENTS CONTAINING THEM
DE3806795A1 (en) 1988-02-29 1989-09-07 Schering Ag POLYMER-TIED COMPLEX IMAGERS, THEIR COMPLEXES AND CONJUGATES, METHOD FOR THEIR PRODUCTION AND PHARMACEUTICAL AGENTS CONTAINING THEM

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020164289A1 (en) * 1995-02-01 2002-11-07 Mcmurry Thomas J. Diagnostic imaging contrast agents with extended blood retention
US6676929B2 (en) * 1995-02-01 2004-01-13 Epix Medical, Inc. Diagnostic imaging contrast agents with extended blood retention

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100010673A1 (en) * 2008-07-11 2010-01-14 Yulun Wang Tele-presence robot system with multi-cast features

Also Published As

Publication number Publication date
US7189879B2 (en) 2007-03-13

Similar Documents

Publication Publication Date Title
US10807953B2 (en) Processes and intermediates for the preparation of Pimavanserin
ES2416032T3 (en) 1 - {[(alpha-isobutanoyloxyethoxy) carbonyl] aminomethyl} -1-crystalline cyclohexaneacetic acid
US11591351B2 (en) Benzyl compound
US7312343B2 (en) Synthesis of α-amino-β-alkoxy-carboxylic acid esters
US20120197041A1 (en) Treprostinil production
WO2017221889A1 (en) Novel diphenylmethane protective agent
SG186708A1 (en) Process for preparing a biphenyl-2-ylcarbamic acid
ES2640374T3 (en) Process for the preparation of fingolimod
CA2856609A1 (en) Process for the preparation of sterol derivatives
US7189879B2 (en) Process for the production of 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride
US8470763B2 (en) Alpha-amino-N-substituted amides, pharmaceutical composition containing them and uses thereof
US9278905B2 (en) Production method for compound comprising amino group and/or hydroxyl group
US20100311991A1 (en) Process for the preparation of docetaxel, its intermediates, and methods for preparation thereof
RU2359958C2 (en) Method for preparation of n-alkyl-o-alkyl urethanes
US5091595A (en) Reduction of diethyl phenylmalonate to 2-phenyl-1,3-propanediol
US8946475B2 (en) Processes for preparing a polymeric compound
US8754261B2 (en) Process for the preparation of O-desmethyl-venlafaxine and salts thereof
JP2008500291A (en) Method for producing 1-hydroxymethyl-1,3,5-triazapentane, trihydrochloride
US20150291522A1 (en) Dendritic core compounds
ES2326800T3 (en) PROCESS FOR THE PRODUCTION OF N- (2,6-DIMETHYL-PHENYL) -2-PIPERAZIN-1-IL-ACETAMIDE.
JPS58109455A (en) N-benzyl amino acid derivative and its preparation
EP0612740B1 (en) Methods of producing pantothenic acid derivative and its starting materials for producing the same
JP3179578B2 (en) Novel pyridine derivative, production method thereof and intermediate thereof
JP2021181407A (en) Hydrate of amidoalcohol compound, production method thereof, and production method of lactone compound
CN116789556A (en) Preparation method of cyclopropoxy ethylamine

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHERING AG, GERMANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PLATZEK, JOHANNES;HUEBNER, JAN;PETROV, ORLIN;REEL/FRAME:017052/0412;SIGNING DATES FROM 20050815 TO 20050826

AS Assignment

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, GERMANY

Free format text: CHANGE OF NAME;ASSIGNOR:SCHERING AKTIENGESELLSCHAFT;REEL/FRAME:020156/0001

Effective date: 20061229

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Expired due to failure to pay maintenance fee

Effective date: 20110313